Barclays Upgrades Helmerich & Payne to Overweight
Barclays analyst David Anderson upgrades Helmerich & Payne (NYSE:HP) from Equal-Weight to Overweight.
Goldman Sachs Maintains Sell on Helmerich & Payne, Lowers Price Target to $38
Goldman Sachs analyst Neil Mehta maintains Helmerich & Payne (NYSE:HP) with a Sell and lowers the price target from $45 to $38.
10 Analysts Have This to Say About Helmerich & Payne
Analysts have provided the following ratings for Helmerich & Payne (NYSE:HP) within the last quarter:
Citigroup Maintains Neutral on Helmerich & Payne, Raises Price Target to $49
Citigroup analyst Scott Gruber maintains Helmerich & Payne (NYSE:HP) with a Neutral and raises the price target from $44 to $49.
Susquehanna Maintains Positive on Helmerich & Payne, Raises Price Target to $62
Susquehanna analyst Charles Minervino maintains Helmerich & Payne (NYSE:HP) with a Positive and raises the price target from $55 to $62.
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell
• Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
Preview: Helmerich & Payne’s Earnings
Helmerich & Payne (NYSE:HP) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement.
Analysts estimate that Helmerich & Payne will report an earnings per share (EPS) of $-0.30.
Goldman Sachs Maintains Sell on Helmerich & Payne, Raises Price Target to $41
Goldman Sachs maintains Helmerich & Payne (NYSE:HP) with a Sell and raises the price target from $36.5 to $41.
Analyst Ratings for Helmerich & Payne
Helmerich & Payne (NYSE:HP) has observed the following analyst ratings within the last quarter: